Overview
Lobbying Costs
1,125,000€
Financial year: Apr 2014 - Mar 2015
Lobbyists (Full time equivalent)
0.5 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Astellas Pharma Europe Limited (APEL)
EU Transparency Register
726065718920-12 First registered on 24 Sep 2015
Goals / Remit
Providing high quality medicines in areas of high unmet medical need
Main EU files targeted
All relevant pharmaceutical and health care initiatives
Address
Head Office
200 Hillswood Drive
Chertsey KT16 0RS
UNITED KINGDOMEU Office
Astellas Pharma BV
Erasmus Park
Brussels 1070
BELGIUM -
People
Total lobbyists declared
2
Employment time Lobbyists 25% 2 Lobbyists (Full time equivalent)
0.5
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 14 Sep 2017
Name Start date End Date Mélanie Yammine 14 Oct 2024 13 Oct 2025 Rachel DIXON 20 Sep 2023 14 Sep 2024 Melanie YAMMINE 20 Sep 2023 14 Sep 2024 Rachel DIXON 29 Mar 2022 29 Mar 2023 Melanie YAMMINE 29 Mar 2022 29 Mar 2023 Melanie YAMMINE 09 Nov 2018 09 Nov 2019 Complementary Information
None declared
Person in charge of EU relations
Ms Barbara McLaughlan (Director Government Affairs EMEA)
Person with legal responsibility
Mr Daniel Schulze (Senior Vice President & General Counsel)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
EFPIA
National pharmaceutical associationsMember organisations
None declared
-
Financial Data
Closed financial year
Apr 2014 - Mar 2015
Lobbying costs for closed financial year
1,125,000€
Other financial info
None
-
EU Structures
Groups (European Commission)
None
ACC
None
Groups (European Parliament)
None
Communication activities
None
Other activities
None declared
Meetings
Meetings
None declared